Wegovy vs Zepbound: 2026 Decision Guide

Zepbound (tirzepatide) outperforms Wegovy (semaglutide) on raw weight loss — 20% vs ~14% at standard doses. But Wegovy now offers a 7.2 mg high-dose version (~19%), oral pill alternatives, and the only cardiovascular indication in the class. Here is the full 2026 decision matrix.

🔬 Insurance coverage collapsed in 2025–2026 — roughly 24 million people lost commercial coverage for one or both drugs across 12 months. Cash-pay pricing now drives most decisions for new patients. The "best" GLP-1 is the one you can actually afford and tolerate long-term.

Zepbound Weight
Loss (15 mg, 72 wk)

Wegovy 7.2 mg
(Mar 2026 New Dose)

Patients Lost
Coverage 2025–2026

Mechanism of Action

How It Works

🥊

Different Targets

Wegovy: semaglutide — pure GLP-1 receptor agonist. Zepbound: tirzepatide — dual GLP-1 + GIP receptor agonist. The added GIP component drives Zepbound's edge on weight loss.

📈

Efficacy Hierarchy

STEP-1 (Wegovy 2.4 mg, 68 wk): ~14% body weight loss. SURMOUNT-1 (Zepbound 15 mg, 72 wk): ~20.2%. New Wegovy 7.2 mg (March 2026): ~19% — narrows the gap.

❤️

Cardiovascular Indication

Wegovy is the only drug in the class with FDA approval to reduce major adverse cardiovascular events (SELECT trial). Zepbound's SURMOUNT-MMO cardiovascular outcomes trial is ongoing.

💰

Cost Structure

List prices: Wegovy ~$1,350/mo, Zepbound ~$1,000/mo. Cash-pay vials/pens: $199–$499/mo. Commercial copays: $25–$150 if covered. Medicare cannot cover for weight loss.

Data

What the Data Shows

Zepbound 15 mg (SURMOUNT-1, 72 wk)

Highest dose head-to-head data

20.2%

Wegovy 7.2 mg (STEP UP, Mar 2026)

New higher Wegovy dose, 72 wk

~19%

Wegovy 2.4 mg (STEP-1, 68 wk)

Standard Wegovy maintenance dose

~14%

Zepbound 5 mg (SURMOUNT-1, 72 wk)

Lowest Zepbound maintenance dose

~15%

Insurance Coverage Loss (2025-2026)

Roughly 12M lost coverage for each drug

~24M total

Bottom Line

Key Takeaways

✅ What We Know

Zepbound (tirzepatide) produces ~6% more weight loss than standard Wegovy (semaglutide) at top doses
Wegovy 7.2 mg (approved March 2026) reaches ~19%, narrowing the gap to ~1% vs Zepbound 15 mg
Wegovy is the only GLP-1 with FDA approval for cardiovascular event reduction (SELECT trial)
Wegovy list price: ~$1,350/mo. Zepbound list price: ~$1,000/mo
Cash-pay options: Wegovy pill $149–$299, Zepbound vials $299–$499 via direct programs
Medicare prohibited from covering either for weight loss alone
12M+ patients each lost commercial coverage 2025-2026
Both share the same GLP-1 black-box thyroid C-cell warning

⚠️ What We Don't Know

When Zepbound CV outcomes will read out (SURMOUNT-MMO ongoing)
Whether higher-dose Wegovy (7.2 mg) matches Zepbound on cardiovascular endpoints
Long-term durability of weight loss off-drug for either
Which is better tolerated head-to-head (no direct comparison trial)
How Medicaid/Medicare coverage will shift through 2027

FAQ

Frequently Asked Questions

Which has better weight loss results — Wegovy or Zepbound?

On standard doses, Zepbound (tirzepatide) wins by margin: ~20.2% mean body weight loss at 15 mg over 72 weeks (SURMOUNT-1) vs ~14% for Wegovy (semaglutide) 2.4 mg at 68 weeks (STEP-1). The new Wegovy 7.2 mg dose approved in March 2026 reaches ~19%, narrowing the gap considerably. Direct head-to-head trial in adults without diabetes (SURMOUNT-5) showed Zepbound superior to Wegovy at top doses.

Which is cheaper without insurance in 2026?

Wegovy oral pill (when approved/available): $149–$299/mo via NovoCare cash-pay. Wegovy injection self-pay: $199–$349/mo. Zepbound vials via LillyDirect: $299/mo (2.5 mg) up to $499/mo (top doses). KwikPen self-pay: $449/mo. List prices remain ~$1,000–$1,350/mo for both — out-of-pocket via the manufacturer programs is the substantial savings.

Which has better insurance coverage in 2026?

Coverage collapsed for both. Roughly 12 million patients lost commercial coverage for Wegovy and another ~12 million for Zepbound between 2025 and 2026. Among those still covered, 88% face restrictions (prior auth, BMI ≥40 requirements, step-therapy). Specifics vary by employer plan — call your insurer before assuming coverage.

Which has fewer side effects?

Both share the GLP-1 class profile: nausea, vomiting, diarrhea, constipation predominate. No reliable direct-comparison data shows one as meaningfully better tolerated. Anecdotally, some users report Zepbound (tirzepatide) has slightly less GI burden at comparable weight-loss rates because the GIP component is theorized to mitigate nausea — this is hypothesis-generating, not proven.

Should I switch from Wegovy to Zepbound?

Common reason: weight-loss plateau on Wegovy after 6+ months. Switching is medically reasonable and has been retrospectively studied with positive results in plateaued patients. Common reason against: insurance covers Wegovy and not Zepbound, or vice versa. Discuss with your prescriber and check current plan formularies before assuming you can switch and stay covered.